AHFS Drug Information 2025

AHFS^® Drug Information^® 2025 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with ongoing updates of therapeutic guideline recommendations, important cautionary information, and other timely and relevant topics related to drug therapy management. AHFS Drug Information^® 2025 Edition is a necessary addition to your pharmacy’s resources.

With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.

Updates in the new edition:

• Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
• Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments
• Contemporary topics such as vaccines and treatments for mPox disease, new RSV treatments and vaccines, safety issues associated with the glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more
• Expanded content on new and emerging gene therapies
• Pharmacogenomic considerations in drug dosing and selection
• Updates to a variety of vaccine monographs including the influenza, COVID-19, pneumococcal, and RSV vaccines with the latest recommendations from the CDC Advisory Committee on Immunization Practices (ACIP)
• Expanded content on off-label uses, real world data and long-term clinical data
• MedWatch alerts, Standardize4Safety concentration standards for IV and oral liquid medications, REMS data, and focused updates based on FDA safety findings
• New content on over 200 new molecular entities (NMEs) or new therapeutic biological products and substantive revisions on approximately 265 medications
• Oncology off-label determinations based on reviews by the AHFS Oncology Expert Committee